- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05225064
Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The goal of the study is to identify strategies that best promote and support COVID vaccine uptake in developing countries, we propose to test a range of scalable social and behavioural interventions. This could help policy makers design and employ interventions that are effective. This is especially valuable in resource constrained contexts where funds and institutional resources can be diverted towards interventions that have proven to work.
In Bihar the intervention will be village-level social mobilization involving community promotion, including in-person vaccine reinforcement, and household-level social mobilization. Some treatment villages will receive household- level interventions with varying intensity (different proportion of households will be visited). There will also an accompanying mask distribution campaign during household visits where the importance of mask-wearing as a complement to vaccine use will be explained.
This ClinicalTrials entry contains results only for the study in Bihar.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Bihar
-
Patna, Bihar, Inde, 800001
- Project Concern International
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Lives in study village
Exclusion Criteria:
- Does not live in study village
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: Control
No vaccine or mask promotion, but access to vaccines increased to match access in intervention villages
|
|
|
Expérimental: Village-level vaccine clinics with monetary, non-monetary, or no incentive
Village-level vaccine clinics with monetary, non-monetary, or no incentive.
Villages are cross-randomized to grocery coupon, food ration, no incentive, or grocery coupon to both community member and community health worker after the community member has received a vaccination.
|
Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
Vaccines are conducted at the household-level rather than the village-level
Village-level social mobilization campaign to be vaccinated
|
|
Expérimental: Household-level vaccination with monetary or no incentive
Household-level vaccination with monetary incentive or no incentive.
Villages are cross-randomized to grocery coupon or no incentive upon receiving vaccination
|
Individuals will be provided with a guaranteed cash payment, entry into a cash lottery, or guaranteed gift of food if they are vaccinated
Vaccines are conducted at the household-level rather than the village-level
Village-level social mobilization campaign to be vaccinated
|
|
Expérimental: Village-level vaccination without incentive, plus mask promotion
Individuals are encourage to attend village-level vaccine clinics but not given any incentive.
Mask distribution and reinforcement activities are conducted in villages at a similar time as vaccine promotion.
|
Vaccines are conducted at the household-level rather than the village-level
Village-level social mobilization campaign to be vaccinated
Individuals are given cloth masks
Individuals who are not wearing masks over their mouth and nose are stopped in public places and encouraged to wear a mask
|
|
Expérimental: Village-level vaccination without incentive
Individuals are encourage to attend village-level vaccine clinics but not given any incentive.
|
Vaccines are conducted at the household-level rather than the village-level
Village-level social mobilization campaign to be vaccinated
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percent of individuals who receive the first, second, or third dose of covid vaccine
Délai: up to 4 weeks (endline may vary depending on estimated uptake rates)
|
Prevalence of vaccination with difference doses
|
up to 4 weeks (endline may vary depending on estimated uptake rates)
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2000031541
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .